BSPGHAN 2021 Virtual Annual Meeting

27- 29 April 2021

TWO YEAR FOLLOW UP OF CHILDREN WITH INFLAMMATORY BOWEL DISEASE (IBD) TREATED WITH VEDOLIZUMAB AND USTEKINUMAB

Subscribe
Notify of
3 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
Rajiv Mohan
Rajiv Mohan
3 months ago
  1. Was there any defined age to start the monoclonal antibodies?
  2. Is 50% of children were primary non responder/secondary loss of response to Vedo/Ustek?
Roxana Mardare
Roxana Mardare
3 months ago
Reply to  Rajiv Mohan

Dear Rajiv,

Thank you for your questions. The main condition for starting Vedolizumab or Ustekinumab was failure of anti-TNF treatment, so there was no age limit. Our youngest patients were 4 years old.
10/27 children failed Vedolizumab or Ustekinumab. Out of these 10 patients, 5 patients were primary nonresponders, while the other 5 had secondary loss of response.
Please let me know if you have more questions. I would be more than happy to respond.

Rajiv Mohan
Rajiv Mohan
3 months ago
Reply to  Roxana Mardare

Thanks Roxana